Search details
1.
Margetuximab in HER2-positive metastatic breast cancer.
Future Oncol
; 19(16): 1099-1112, 2023 May.
Article
in English
| MEDLINE | ID: mdl-37170847
2.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Proc Natl Acad Sci U S A
; 116(52): 26823-26834, 2019 Dec 26.
Article
in English
| MEDLINE | ID: mdl-31826955
3.
Management of hormone receptor-positive, human epidermal growth factor 2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 190(2): 189-201, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34515904
4.
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Breast Cancer Res Treat
; 189(1): 187-202, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34173924
5.
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
Br J Cancer
; 120(3): 331-339, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30555156
6.
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Breast Cancer Res Treat
; 177(2): 427-435, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31218477
7.
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
Proc Natl Acad Sci U S A
; 113(43): E6600-E6609, 2016 10 25.
Article
in English
| MEDLINE | ID: mdl-27791031
8.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Cancer Res Treat
; 167(3): 731-740, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29110152
9.
Targeting HER2 for the treatment of breast cancer.
Annu Rev Med
; 66: 111-28, 2015.
Article
in English
| MEDLINE | ID: mdl-25587647
10.
Retrospective review of genomic testing in breast cancer: Does it improve outcome?
Breast Cancer Res Treat
; 163(1): 191-195, 2017 May.
Article
in English
| MEDLINE | ID: mdl-28224382
11.
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis.
Breast Cancer Res
; 17: 3, 2015 Jan 09.
Article
in English
| MEDLINE | ID: mdl-25572662
12.
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Lancet Oncol
; 15(2): 156-63, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24439313
13.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Cancer Res
; 16(5): 430, 2014 Sep 11.
Article
in English
| MEDLINE | ID: mdl-25212826
14.
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Breast Cancer Res Treat
; 144(2): 263-72, 2014 Apr.
Article
in English
| MEDLINE | ID: mdl-24554387
15.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 362-371, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-38236590
16.
Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Human Epidermal Growth Factor Receptor 2-Expressing Metastatic Breast Cancer.
JCO Oncol Pract
; 19(8): 539-546, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37207306
17.
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
Clin Cancer Res
; 29(8): 1468-1476, 2023 04 14.
Article
in English
| MEDLINE | ID: mdl-36716289
18.
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins.
Cancer Res Commun
; 3(8): 1551-1563, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37587913
19.
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Cell Rep
; 42(8): 112821, 2023 Aug 29.
Article
in English
| MEDLINE | ID: mdl-37467106
20.
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.
iScience
; 26(1): 105799, 2023 Jan 20.
Article
in English
| MEDLINE | ID: mdl-36619972